Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.77 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.77 |
| ▸ | KDR | P35968 | 9/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.70 |
| ▸ | RET | P07949 | 4/20 | 0.70 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.70 |
| ▸ | SRC | P12931 | 3/20 | 0.70 |
| ▸ | ABL1 | P00519 | 3/20 | 0.70 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.70 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.70 |
| ▸ | PLK4 | O00444 | 2/20 | 0.70 |
| ▸ | AURKA | O14965 | 2/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 2/20 | 0.70 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
| ▸ | LYN | P07948 | 2/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.70 |
| ▸ | AXL | P30530 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257980 | 0.96 | RAF1 (0.82) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL5319531 | 0.94 | KDR (0.67) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL10163311 | 0.91 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL12391532 | 0.91 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL19888730 | 0.90 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL16620832 | 0.90 | RAF1 (0.74) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL28430251 | 0.90 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL4732730 | 0.88 | RAF1 (0.71) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL16628087 | 0.87 | KDR (0.83) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL13458871 | 0.87 | RAF1 (0.70) | RAF1EPHX2KDRMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2478361-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | Avila Therapeutics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | RAF1 117/4885EPHX2 2018/4885KDR 2005/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | RAF1 117/4885EPHX2 2018/4885KDR 2005/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | RAF1 109/4885EPHX2 2120/4885KDR 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.